Thrombolex, Inc.

Thrombolex, Inc. is a commercial-stage medical device company headquartered in New Britain, Pennsylvania, specializing in endovascular treatment of arterial and venous thromboembolic (A+VTE) conditions. The company develops the BASHIR™ Family of Endovascular Catheters, which employ a hybrid pharmaco-mechanical lysis (PML) platform combining mechanical clot fragmentation with targeted pharmacological thrombolytic delivery. The BASHIR product line includes three main catheter variants: the standard BASHIR Endovascular Catheter (7F and 8F sizes) for peripheral and pulmonary vessels; the BASHIR S-B (short basket) for tortuous and shorter vessel anatomy; and the BASHIR PLUS for extensive thrombus burden with extended infusion capability along the catheter shaft. The company's mechanism uses an expandable infusion basket allowing physician-controlled, selective fluid infusion to optimize clot burden resolution while minimizing systemic exposure to thrombolytics. Thrombolex is conducting active clinical trials including the RESCUE-II study and the RAPID-PE study, which evaluate on-the-table single-session protocols for pulmonary embolism treatment. The company has secured Series A financing and maintains partnerships with diagnostic platforms to advance clinical adoption. Products are marketed to interventional cardiologists and interventional radiologists for acute PE and venous thrombus intervention in hospital-based catheterization labs and interventional suites.